[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@BlaseBio](/creator/twitter/BlaseBio) "$SRPT seems like they have FDA teflon - $400M annual cost savings XX% RIF (500 employees) - $513M in 2Q25 revenues - Black box warning for ELEVIDYS - additional prophylactic immunosuppression for non-ambulant patients"  [@BlaseBio](/creator/x/BlaseBio) on [X](/post/tweet/1945575838738501764) 2025-07-16 20:06:41 UTC XXX followers, 1180 engagements "Definitely a bit shocked by the $REPL CRL. Would love to know if there's something that was wrong with the data/trial because a blank rejection seems harsh in light of $IOVA trial and the unmet need. I think people saying this won't have industry-wide impacts are naive"  [@BlaseBio](/creator/x/BlaseBio) on [X](/post/tweet/1947650154791571502) 2025-07-22 13:29:17 UTC XXX followers, 2074 engagements "@IC50_cent In a world where this is true what are the issues with REPL's current confirmatory trial I'd love to be proven wrong here- because it would show there's an issue with the data not the FDA but I can't really find a coherent argument"  [@BlaseBio](/creator/x/BlaseBio) on [X](/post/tweet/1947680657024466974) 2025-07-22 15:30:29 UTC XXX followers, XXX engagements "@IC50_cent I'm not sure that's a fair comparison though. Most pts were treated with pd-1 mono and there's a far less stringent definition of progression (pts who progress anytime versus progress while on PD-1). High skew towards superficial/injectable is fair but is that CRL worthy"  [@BlaseBio](/creator/x/BlaseBio) on [X](/post/tweet/1947657659848478899) 2025-07-22 13:59:06 UTC XXX followers, XXX engagements "Whatever happened to the $CRDL acute myocarditis data coming in 2Q25"  [@BlaseBio](/creator/x/BlaseBio) on [X](/post/tweet/1943373634820596087) 2025-07-10 18:15:55 UTC XXX followers, 1461 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@BlaseBio
"$SRPT seems like they have FDA teflon - $400M annual cost savings XX% RIF (500 employees) - $513M in 2Q25 revenues - Black box warning for ELEVIDYS - additional prophylactic immunosuppression for non-ambulant patients"
@BlaseBio on X 2025-07-16 20:06:41 UTC XXX followers, 1180 engagements
"Definitely a bit shocked by the $REPL CRL. Would love to know if there's something that was wrong with the data/trial because a blank rejection seems harsh in light of $IOVA trial and the unmet need. I think people saying this won't have industry-wide impacts are naive" @BlaseBio on X 2025-07-22 13:29:17 UTC XXX followers, 2074 engagements
"@IC50_cent In a world where this is true what are the issues with REPL's current confirmatory trial I'd love to be proven wrong here- because it would show there's an issue with the data not the FDA but I can't really find a coherent argument" @BlaseBio on X 2025-07-22 15:30:29 UTC XXX followers, XXX engagements
"@IC50_cent I'm not sure that's a fair comparison though. Most pts were treated with pd-1 mono and there's a far less stringent definition of progression (pts who progress anytime versus progress while on PD-1). High skew towards superficial/injectable is fair but is that CRL worthy" @BlaseBio on X 2025-07-22 13:59:06 UTC XXX followers, XXX engagements
"Whatever happened to the $CRDL acute myocarditis data coming in 2Q25" @BlaseBio on X 2025-07-10 18:15:55 UTC XXX followers, 1461 engagements